SCHEMBL23975981

SCHEMBL23975981

CC(C)C(C(=O)O)N(C)c1nc(-c2ccccn2)nc2c1CCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.42
CFTR P13569 6/20 0.40
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37
LMNA P02545 1/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 1/20 0.35
SPR P35270 1/20 0.35
METAP2 P50579 1/20 0.35
METAP1 P53582 1/20 0.35
NPC1 O15118 1/20 0.35
AGTR1 P30556 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225191 1.00 PDE10A (0.42) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23975952 0.89 PDE10A (0.40) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL30225210 0.89 PDE10A (0.40) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL30118774 0.86 PDE10A (0.39) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23975718 0.86 PDE10A (0.39) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL30118660 0.86 PDE10A (0.39) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23986923 0.86 PDE10A (0.39) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23975848 0.86 PDE10A (0.39) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23976404 0.85 PDE10A (0.41) PDE10ACFTRTDP1MEN1KMT2A
SCHEMBL23976570 0.80 PDE10A (0.40) PDE10ACFTRTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 PDE10A 3407/4885CFTR 1596/4885TDP1 1304/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI PDE10A 2677/4885CFTR 334/4885TDP1 2891/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI PDE10A 2677/4885CFTR 334/4885TDP1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.